The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure
Open accessAbstract
Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A number of treatments ranging from pharmacological such as intravenous iron, device therapies such as cardiac resynchronization therapy, and non-pharmacological options such as aerobic exercise are associated with improved exercise capacity.
“A number of treatments ranging from pharmacological such as intravenous iron, device therapies such as cardiac resynchronization therapy, and non‐pharmacological options such aerobic exercise are associated with improved exercise capacity. 41 , 42 , 43”
From Prioritizing symptom management in the treatment of chronic heart failure (2020) · cites this paper as [41]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 19,890
Self-citationAhmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
Ponikowski, P. P., van Veldhuisen, D. J., Colet, J. C., Ertl, G., Michel Komajda, N., VIu, M., McDonagh, T. A., Parkhomenko, A. N., Tavazzi, L., Levesque, V., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu385 · Cited by 1,240
Kantor, P. F., Lucien, A., Kozak, R., & Lopaschuk, G. D. (2000) · Circulation Research · doi:10.1161/01.res.86.5.580 · Cited by 817
Piepoli, M. F., Conraads, V. M., Corrà, U., Dickstein, K., Francis, D. P., Jaarsma, T., McMurray, J. J. V., Pieske, B. M., Piotrowicz, E., Schmid, J., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr017 · Cited by 748
Iron deficiency in chronic heart failure: an international pooled analysis
Klip, I. T., Comin-Colet, J., Voors, A. A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D. J., Rosentryt, P., Torrens, A., Polonski, L., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.017 · Cited by 736
Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome
Obi, Y., Kim, T. H., Kovesdy, C. P., Amin, A., & Kalantar‐Zadeh, K. (2015) · Cardiorenal Medicine · doi:10.1159/000441283 · Cited by 615
Okonko, D. O., Grzesło, A., Witkowski, T. G., Mandal, A. K. J., Slater, R. M., Roughton, M., Földes, G., Thum, T., Majda, J., Banasiak, W., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.036 · Cited by 576
Lewis, G. D., Malhotra, R. K., Hernandez, A. F., McNulty, S. E., Smith, A. L., Felker, G. M., Tang, W. H. W., LaRue, S., Redfield, M. M., Semigran, M. J., et al. (2017) · JAMA · doi:10.1001/jama.2017.5427 · Cited by 490
van Veldhuisen, D. J., Ponikowski, P. P., van der Meer, P., Metra, M., Böhm, M., Doletsky, A., Voors, A. A., Macdougall, I. C., Anker, S. D., Roubert, B., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027497 · Cited by 422
Toblli, J. E., Lombraña, A., Duarte, P. J., & Gennaro, F. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.029 · Cited by 415
Anker, S. D., Kirwan, B., van Veldhuisen, D. J., Filippatos, G. S., Colet, J. C., Ruschitzka, F. T., Lüscher, T. F., Arutyunov, G. P., Motro, M., Mori, C., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.823 · Cited by 411
Disordered Iron Homeostasis in Chronic Heart Failure
Okonko, D. O., Mandal, A. K. J., Missouris, C. G., & Poole-Wilson, P. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.040 · Cited by 373
Jankowska, E. A., Tkaczyszyn, M., Suchocki, T., Drozd, M., von Haehling, S., Doehner, W., Banasiak, W., Filippatos, G. S., Anker, S. D., & Ponikowski, P. P. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.473 · Cited by 346
Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
Hampton, J. R., van Veldhuisen, D., Kleber, F. X., Cowley, A., Ardia, A., Block, P., Cortina, A., Cserhalmi, L., Folláth, F., Jensen, G. B., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10488-8 · Cited by 345
Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure
Bolger, A. P., Bartlett, F. R., Penston, H. S., O’Leary, J., Pollock, N., Kaprielian, R., & Chapman, C. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.015 · Cited by 292
Fragasso, G., Palloshi, A., Puccetti, P., Silipigni, C., Rossodivita, A., Pala, M. G., Calori, G., Alfieri, O., & Margonato, A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.060 · Cited by 270
Ekman, I., Chassany, O., Michel Komajda, N., Böhm, M., BORER, J. S., Ford, I., Tavazzi, L., & Swedberg, K. B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr343 · Cited by 206
Trimetazidine: a meta-analysis of randomised controlled trials in heart failure
Gao, D., Ning, N., Niu, X., Hao, G., & Meng, Z. (2010) · Heart · doi:10.1136/hrt.2010.208751 · Cited by 195
Vitale, C., WAJNGATEN, M., Sposato, B., Gebara, O., Rossini, P. M., Fini, M., Volterrani, M., & Rosano, G. M. C. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.034 · Cited by 183
Self-citationPrevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure
Cleland, J. G. F., Zhang, J., Pellicori, P., Dicken, B., Dierckx, R., Shoaib, A., Wong, K., Rigby, A. S., Goode, K. M., & Clark, A. L. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1161 · Cited by 179
Additional Use of Trimetazidine in Patients With Chronic Heart Failure
Zhang, L., Lu, Y., Jiang, H., Zhang, L., Sun, A., Zou, Y., & Ge, J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.027 · Cited by 164
Napoli, P. D., Taccardi, A. A., & Barsotti, A. (2005) · Heart · doi:10.1136/hrt.2003.031310 · Cited by 141
Rosano, G. M. C., Vitale, C., Sposato, B., Mercuro, G. G., & Fini, M. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-16 · Cited by 137
Self-citationUsmanov, R. I., Zueva, E. B., Silverberg, D. S., & Shaked, M. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.2.236 · Cited by 130
Volterrani, M., Cice, G., Caminiti, G., Vitale, C., D’Isa, S., Filardi, P. P., Acquistapace, F., Marazzi, G., Fini, M., & Rosano, G. M. C. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.06.098 · Cited by 129
Self-citationPacker, M., The Principal Investigators of the Reflect Study, Narahara, K. A., Elkayam, U., Sullivan, J. M., Pearle, D. L., Massie, B. M., & Creager, M. A. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90816-j · Cited by 119
Fragasso, G., Rosano, G. M. C., Baek, S. H., Sisakian, H. S., Napoli, P. D., Alberti, L., Calori, G., Kang, S., Sahakyan, L. G., Sanosyan, A., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.123 · Cited by 96
Self-citationTrimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect
Belardinelli, R., Solenghi, M., Volpe, L., & Purcaro, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm071 · Cited by 85
Sarullo, F. M., Fazio, G., Puccio, D., Fasullo, S., Paterna, S., Novo, S., & Pasquale, P. D. (2010) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248410370326 · Cited by 56
Is Treatment with Trimetazidine Beneficial in Patients with Chronic Heart Failure?
Zhou, X., & Chen, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094660 · Cited by 53
Barré, J., Ledudal, P., Oosterhuis, B., Brakenhoff, J. P. G., Wilkens, G., Sollie, F. A. E., & Tran, D. (2003) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.350 · Cited by 36
Bagriy, A. E., Schukina, E. V., Samoilova, O. V., Pricolota, O. A., Malovichko, S. I., Pricolota, A. V., & Bagriy, E. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0185-5 · Cited by 36
Sisakian, H. S., Torgomyan, A., & Barkhudaryan, A. (2007) · Acta Cardiologica · doi:10.2143/ac.62.5.2023413 · Cited by 32
Trimetazidine improves exercise tolerance in patients with ischemic heart disease
Zhao, Y., Peng, L., Luo, Y., Li, S., Zheng, Z., Dong, R., Zhu, J., & Liu, J. (2015) · Herz · doi:10.1007/s00059-015-4392-2 · Cited by 32
Metabolic Modulation: A New Therapeutic Target in Treatment of Heart Failure
Palaniswamy, C., Mellana, W. M., Selvaraj, D. R., & Mohan, D. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181d70453 · Cited by 25
Génissel, P., Chodjania, Y., Démolis, J., Ragueneau, I., & Jaillon, P. (2004) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190575 · Cited by 19
Trimetazidine Shortens QTc Interval in Patients With Ischemic Heart Failure
Zemljič, G., Bunc, M., & Vrtovec, B. (2009) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409354601 · Cited by 17
The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelins
Milinković, I., Rosano, G. M. C., Lopatin, Y. M., & Seferovic, P. M. (2016) · Cardiac failure review · doi:10.15420/cfr.2016:13:1 · Cited by 12
Self-citationCardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure
Pereira-Barretto, A. C. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0257-6 · Cited by 10
Rosano, G. M. C., Vitale, C., & Volterrani, M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0030-9 · Cited by 7
Self-citationPharmacological management of chronic heart failure: old drugs, new drugs and new indications
Lim, W. Y., & Woldman, S. (2013) · British Journal of Hospital Medicine · doi:10.12968/hmed.2013.74.sup2.c18 · Cited by 2
Flagged first, then by citations
Cited by
Sorted by citations
Prioritizing symptom management in the treatment of chronic heart failure
Koshy, A. O., Gallivan, E. R., McGinlay, M., Straw, S., Drozd, M., Toms, A. G., Gierula, J., Cubbon, R. M., Kearney, M. T., & Witte, K. K. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12875 · Cited by 66
Frailty in patients with heart failure
Vitale, C., & Uchmanowicz, I. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz238 · Cited by 40
Self-citationExercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
Nijholt, K. T., Sánchez-Aguilera, P., Voorrips, S. N., de Boer, R. A., & Westenbrink, B. D. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2407 · Cited by 36
Sindone, A. P., Doehner, W., Manito, N., McDonagh, T. A., Solal, A. C., Damy, T., Núñez, J. E., Pfister, O., van der Meer, P., & Colet, J. C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11112976 · Cited by 18
Monitoring of iron status in patients with heart failure
Jankowska, E. A., Tkaczyszyn, M., Drozd, M., & Ponikowski, P. P. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz231 · Cited by 15
Care plans for the older heart failure patient
Hill, L., Carson, M. A., & Vitale, C. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz243 · Cited by 11
Self-citationPharmacology of Ivabradine and the Effect on Chronic Heart Failure
Zhou, Y., Wang, J., Meng, Z., Zhou, S., Peng, J., Chen, S., Wang, Q., & Sun, K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190809093144 · Cited by 10
Sympathetic and hemodynamic responses to exercise in heart failure with preserved ejection fraction
Manabe, K., D’Souza, A. W., Washio, T., Takeda, R., Hissen, S. L., Akins, J. D., & Fu, Q. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1148324 · Cited by 9
Clinical case: heart failure and ischaemic heart disease
Rosano, G. M. C. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suz046
Self-citation
Metadata
- Authors
- Vitale, C., Spoletini, I., & Rosano, G. M.
- Affiliations
- IRCCS San Raffaele Roma (IT)
- Venue
- Cardiac failure review
- Publisher
- Radcliffe Medical Media Ltd
- Published
- 2018
- Volume
- 4
- Issue
- 1
- Pages
- 1
- ISSN
- 2057-7540 (ISSN-L)
- PMC
- PMC5971671
- OpenAlex
- W2803764206
- Cited by
- 9
- References
- 47
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 5
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Cardiac failure review (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Keywords
- heart failure, exercise capacity, exercise intolerance, pharmacological interventions, ivabradine, trimetazidine, intravenous iron, functional capacity, quality of life, physical performance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
